Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the ...

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society ...

The 700,000 square-foot facility is expected to create 400 high-wage manufacturing jobs once operational.

On Sunday, President Trump posted to Truth Social that he planned on implementing a most-favored-nation policy for ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...